Jazz Pharmaceuticals JAZZ Sunosi — Total revenues
Discontinued — last reported Q4 '24
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 26, 2025, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's sunosi — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's sunosi — total revenues?
- Jazz Pharmaceuticals (JAZZ) reported sunosi — total revenues of $0 in Q4 2024.
- What is the long-term trend for Jazz Pharmaceuticals's sunosi — total revenues?
- Over 3 years (2021 to 2024), Jazz Pharmaceuticals's sunosi — total revenues has grown at a -100.0% compound annual growth rate (CAGR), from $57.91M to $0.
- What does sunosi — total revenues mean?
- The total sales revenue generated by a specific pharmaceutical product.
- How do you interpret sunosi — total revenues?
- An increase indicates growing market penetration or successful commercial execution for the specific drug, while a decrease may signal patent expiration, increased competition, or a strategic divestiture.
- How does sunosi — total revenues compare across companies?
- Comparable to product-specific revenue lines reported by other biopharmaceutical companies, often categorized under specific therapeutic franchises or individual brand performance disclosures.